Posted by Michael Wonder on 07 Jun 2025
European Commission approves Duvyzat for the treatment of Duchenne muscular dystrophy
6 June 2025 - The approval is based on Phase 3 EPIDYS trial data that demonstrated meaningful treatment benefits in ambulant patients.
Italfarmaco announced today that the European Commission has granted conditional marketing authorisation for Duvyzat (givinostat), a novel histone deacetylase inhibitor.
